Futures rise after MSFT earnings 📈

Results from First Republic Bank and other major companies sent US benchmarks tumbling on Tuesday. The Dow fell 1.0%, while the S&P 500 lost 1.5%, and the Nasdaq tumbled to a 1.9% loss. The small-cap Russell 2K underperformed with a 2.4% decline.

Futures are on the rise after Microsoft released strong earnings results on Tuesday evening. S&P 500 contracts are currently up 0.1%.

A Crash Proof Portfolio?

If you're worried "transitory" inflation and "mild" recession will be worse than expected...

You're not alone.

BUT one asset 99% of investors miss helps protect your portfolio and has outpaced the S&P by 131% over the past 26 years.

Art.

Historically, you've needed millions to invest, but one platform lets you buy shares in famous paintings for as little as $20!

Skip the waitlist and join Masterworks today with this private link.

📈 Microsoft Earnings Boost Stocks

Upbeat earnings results from Microsoft put the market in an exuberant mood coming into today's session. The tech giant reported stronger-than-expected figures for earnings and revenues.

Microsoft is rallying after a strong earnings report.

The tech giant reported earnings and revenues that stopped analyst expectations, and investors are optimistic about the company's plans for AI.

Microsoft generated EPS of $2.45 per share on revenues of $52.9 billion, which topped the consensus of $2.23 per share on $51.02 billion.

The company reported lower-than-expected growth estimates for its lucrative Azure segment, but the market took the news well.

The news prompted several analyst upgrades. However, news just broke that UK regulators blocked the firm's planned acquisition of Activision Blizzard [ATVI].

MSFT is up 7.4% in the premarket and leading the S&P 500.

My Take: MSFT is getting a big boost from its ChatGPT deal and other AI efforts. There could be more gains ahead for this stock.

A regulatory ruling is giving IN8bio a big boost.

Early this morning, the biotech company said the Food & Drug Administration awarded an Orphan Drug Designation for INB-400 & INB-410.

The designations cover treatment for a broad range of malignant tumors, including newly diagnosed glioblastoma.

IN8bio said it expects to begin patient enrollment for a phase 2 trial of INB-400 expected to begin in the second half.

The news rallied INAB to a 41.3% gain in the premarket.

My Take: INAB has made dramatic moves in the past two days. It will be interesting to see which way it goes over the next few days.

Sobr Safe is moving higher after an early-morning product announcement.

The non-invasive alcohol detection firm announced a new partnership with Think Twice to advocate for its SOBRsafe technology to enterprise employers.

Think Twice supplies public safety products and programs through the U.S. and Canada, with over 5,000 customers across numerous industries.

Under the terms of the agreement, Think Twice will encourage its customers to drop traditional breathalyzers in favor of SOBRsafe.

SOBR is up 20.7% following the early morning announcements.

My Take: SOBR has made some progress lately, and the market seems to be buying into its new technology. This stock could have some promise.

An analyst rating is rallying shares of Panbela Therapeutics.

HC Wainwright & Co analyst Joseph Pantginis initiated coverage on the clinical-stage biopharma firm with a "buy" rating and a $7 price target.

The note dropped this morning, and the news immediately sparked a run up in shares of PBLA.

PBLA is up 17.9%, and it's one of the top-performing NASDAQ stocks.

My Take: PBLA's chart is very unimpressive, but this analyst rating could be a good start for the stock.

Thermo Fisher Scientific Inc [TMO] ... AM
Boeing Company (The) [BA] ... AM
American Tower Corporation (Reit) Reit [AMT] ... AM
Automatic Data Processing, Inc. [ADP] ... AM
Boston Scientific Corporation [BSX] ... AM
Cme Group Inc. [CME] ... AM
Humana Inc. [HUM] ... AM
Meta Platforms, Inc. [META] ... PM
Servicenow, Inc. [NOW] ... PM
Waste Management, Inc. [WM] ... PM